Gyros AB Appoints Dr. Claus Braestrup to the Board of Directors
News Jan 28, 2013
He is also a Member of the Advisory Board of Nordic Biotech and BankInvest BioMedical Venture. Dr. Braestrup is a Member of The Royal Danish Scientific Society and The Academy of Technical Sciences. He holds M.Sc. degrees in Chemical Engineering and Biochemistry, and a Doctorate in Medical Science from the University of Copenhagen.
Dr. Braestrup was previously President and Chief Executive Officer at H. Lundbeck A/S. He also formerly held the positions of Vice President of Pharmaceutical Research, President of the CNS Division, and President of the Diabetes Care Division at Novo Nordisk A/S, and Head of Preclinical Drug Research with Schering AG.
Erik Walldén, CEO at Gyros, commented: “We welcome Claus to the Board of Directors. His excellent scientific background and many years’ experience within the biotech and pharmaceutical industry will be a great asset to Gyros.”
Biomillenia Leverages QIAGEN Bioinformatics in Microbiome-on-a-Chip Discovery of Unculturable MicrobesNews
Microbiome-on-a-chip technology capable of culturing, screening and isolating bacteria in single step while demonstrating targeted benefits. QIAGEN’s Microbial Genomics Pro Suite enables analysis of microbial sequences and microbiomes.READ MORE
Fast, Accurate Parasite Detection Method DevelopedNews
A research team from the University of Macau has developed a fast, accurate, and convenient point-of-care pathogen detection method with the help of a digital microfluidic system.READ MORE
Cell-weighing Method Could Help Doctors Choose Cancer DrugsNews
Researchers at MIT have now shown that they can use a new type of measurement to predict how drugs will affect cancer cells taken from multiple-myeloma patients.READ MORE